Unlock instant, AI-driven research and patent intelligence for your innovation.

A method of improving liver function

A technology of liver function and liver lipid, applied in the field of treating poor liver function, treating poor liver function or improving liver function, can solve the problems of absence and loss of insulin response, etc.

Inactive Publication Date: 2015-04-01
纳亚代谢有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] In type 2 diabetes, also known as non-insulin dependent diabetes mellitus (NIDDM) or late-onset diabetes, insulin levels are initially normal, but target cells in the body lose their response to insulin
In fact, there are no FDA-approved treatments or guidelines for approving drugs for NAFLD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method of improving liver function
  • A method of improving liver function
  • A method of improving liver function

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] The influence of embodiment 1-methazolamide on the ALT level of patients with type 2 diabetes mellitus

[0093] The safety and efficacy of methazolamide (40 mg administered twice daily) as a potential treatment for type 2 diabetes were evaluated in a 24-week randomized, placebo-controlled, double-blind clinical trial. The primary efficacy endpoint of the clinical trial was after 24 weeks of treatment, when using methazolamide, compared with placebo, HbA 1c Decrease from baseline (ΔHbA 1c ). The primary safety measure was the effect of methazolamide on venous blood gas parameters, a measure of acidosis, compared with placebo.

[0094] The initial participants in the clinical trial were type 2 diabetic patients who had not experienced any antidiabetic treatment before entering the trial. The trial was expanded to include subjects who had been on metformin for at least 3 months prior to trial entry (MET) and had been on a stable metformin dose for at least 8 weeks. T...

Embodiment 2

[0107] The effect of embodiment 2-methazolamide on db / db mouse liver lipid

[0108] All reagents were purchased from Sigma-Aldrich (Australia). Dosing solutions of methazolamide acetazolamide in 65:35 (v / v) sterile saline:PEG400 were prepared fresh daily, protected from light and stored at room temperature. Male db / db mice (Animal Resource Centre, Australia) were maintained with free access to water and food (standard rodent diet: Barastoc Rat and Mouse, Ridley Agriproducts, Australia). Room temperature was maintained at 21 ± 2°C with a humidity of 40%-70% while a 12-h light / dark cycle was performed. Mice (n=4 per group) were treated daily with methazolamide (50 mg / kg / day) or vehicle by single-dose oral gavage for 9 days.

[0109]Blood samples were taken daily from the tip of the tail of each mouse, and glucose levels were measured with a glucometer (AccuCheck II; Roche, Australia). At the end of the study, animals were sacrificed humanely and a portion of liver tissue (l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient.

Description

technical field [0001] The present disclosure relates generally to the use of methazolamide in therapy. The present disclosure also relates to treating poor liver function, or improving liver function, and / or lowering or decreasing ALT in a patient. The present disclosure also relates to the use of methazolamide and compositions and medicaments containing it to treat liver dysfunction or improve liver function in a patient. Background technique [0002] Reference to any prior publication (or information derived therefrom) or any known content in this specification is not and should not be considered an endorsement or acknowledgment or suggestion of any kind that said prior publication (or information derived therefrom) information) or what is known forms part of the common general knowledge in the field of endeavor to which this description relates. [0003] Serum alanine aminotransferase, also known as alanine aminotransferase (ALT), is a transaminase found in high concen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/433A61P1/16
CPCA61K31/155A61K31/433A61K2300/00A61K45/06A61P1/16A61P3/04A61P3/06A61P43/00A61P3/10
Inventor 肯·瓦尔德盖伊·克里普纳杰夫·尼克尔森
Owner 纳亚代谢有限公司